SPLITOAK STRATEGIES LLC

Lobbying for BRISTOL-MYERS SQUIBB · Global biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $10,000.00 income · posted Jul 21, 2025

Bills named in this filing 3

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 1

Medicare/Medicaid

Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D H.R. 1 H.R.946/S.1862 - ORPHAN Cures Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.